VivaBioCell develops, manufactures and commercializes automated solutions for the manufacturing of advanced therapy medicinal products, for both research and clinical applications. The company, born as a university spin-off, has evolved over the years delivering several projects in the field of tissue engineering, medical devices and cell cultures automation, aimed at the development of new clinical applications. In 2015 VivaBioCell was acquired by ImmunityBio Inc. (formerly NantCell Inc.), a subsidiary of NantWorks LLC group (Culver City, California), an ecosystem of companies focused on biotech, healthcare AI, and mobility. This journey has brought into the company what we consider our main assets: the deep and diversified knowledge of our multidisciplinary team, together with strong and enduring partnerships with best-in-class clinical and technology stakeholders. Our mission is to provide smart and cost-effective solutions that allow for the improvement and standardization of advanced therapies manufacturing. Our systems together with the strong commitment in supporting the customers during all phases of set-up and validation, allow for a safe seamless conversion of a manual protocol into a high-standardized scalable process, drawing the attention on risk reduction and cost containment, while maintaining regulatory and quality requirements. Indeed, we truly want to inspire the application and diffusion of sustainable advanced therapies, with the long-term vision of bridging regenerative medicine into the mainstream worldwide clinical practice.
Link esterno per VivaBioCell
Via del Cotonificio, 127
Udine, Friuli-Venezia Giulia 33100, IT
Via Nazionale, 124
Tavagnacco, Friuli-Venezia Giulia 33010, IT
VivaBioCell ha diffuso questo post
At ImmunityBio we are revolutionizing cancer and infectious disease treatments with a powerful new approach. Our therapies are designed to do more than today's treatments by boosting the body's own immune response for long-term protection. #NextGenImmunotherapy #ImmunityBio
VivaBioCell ha diffuso questo post
ImmunityBio founder Dr. Patrick Soon-Shiong shared his remarkable journey on the Healthcare Unfiltered podcast. From apartheid-era South Africa to global success, he overcame adversity, pioneered cancer treatments, and continues to make a difference. Listen: https://lnkd.in/gasdpHXi
VivaBioCell ha diffuso questo post
Exciting news! ImmunityBio is partnering with the National Cancer Institute (NCI) on a groundbreaking U.S. cancer vaccine study targeting Lynch syndrome. Learn more at: https://lnkd.in/gz9jKTG and https://lnkd.in/gnkTPQsW.
VivaBioCell ha diffuso questo post
ImmunityBio is happy to support the Society for Immunotherapy of Cancer (SITC’s) annual fundraiser to raise money for cancer research. The Checkpoints, a physician band we sponsored, played at Buddy Guy's Legends on Sunday. Learn more: https://lnkd.in/geRGJB97
Unisciti al team VBC, we're hiring! Applica ora: https://lnkd.in/d8ZSEXfM
VivaBioCell ha diffuso questo post
ImmunityBio is happy to support the Society for Immunotherapy of Cancer (SITC’s) annual fundraiser to raise money for cancer research. The Checkpoints, a physician band we sponsored, played at Buddy Guy's Legends on Sunday. Learn more: https://lnkd.in/geRGJB97
VivaBioCell ha diffuso questo post
The FDA's green light for our first-in-class IL-15 receptor marks a new era in treating non–muscle-invasive bladder cancer (NMIBC). In this interview with Urology Times Dr. Patrick Soon-Shiong sheds light on the pivotal approval. Learn More: https://lnkd.in/gXxhSPrf
VivaBioCell ha diffuso questo post
The FDA's green light for our first-in-class IL-15 receptor marks a new era in treating non–muscle-invasive bladder cancer (NMIBC). In this interview with Urology Times Dr. Patrick Soon-Shiong sheds light on the pivotal approval. Learn More: https://lnkd.in/gXxhSPrf
VivaBioCell ha diffuso questo post
ImmunityBio is at the forefront of transforming bladder cancer treatment. Our innovative research aims to develop more effective therapies. Visit us to learn about our groundbreaking work and how we're making a difference: https://lnkd.in/gJmy4pZg #BladderCancer
VivaBioCell ha diffuso questo post
Today, the FDA approved a treatment for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). This novel immunotherapy activates the body’s natural killer and killer T-cell immune system to attack tumor cells. We extend our thanks and gratitude for the dedication and involvement of our clinical trial participants and investigators, whose efforts have made the advancement of new treatments possible. Learn more about this major development in our press release: https://lnkd.in/gU-wYZfp #BladderCancer #Immunotherapy